

ASX Release

Oventus Medical establishes platform for growth – Audited FY16 Financial Results

Key Points:

- **Strong financial position for future growth**
- **Two devices cleared by FDA and TGA**
- **Strong IP portfolio**
- **3D manufacturing process established for global ramp up**
- **Clinical trials underway**

Brisbane, Australia 29th September 2016: Medical device sleep apnoea and snoring disorder company Oventus Medical Ltd is pleased to release its 2015-16 audited financial results.

The company has established a strong platform for growth delivering unique, effective mouth guard devices to treat sufferers of sleep apnoea and snoring around the world.

Oventus has achieved a number of significant milestones in recent months, including:

- Clearance by the US Food and Drug Administration and Australia's Therapeutic Goods Administration for O₂Vent™ Mono and new O₂Vent™ T devices
- Expanded its clinical program to further validate the Oventus airway
- Formed an Australian Scientific Advisory Committee
- Accelerated the training program for Australian dentists to deliver O₂Vent™ devices.

Clearance by regulators in the US and Australia of Oventus' O₂Vent™ Mono and new O₂Vent™ T devices paves the way for an accelerated rollout in each market, as well as establishing a clear path for launches in Europe and Asia. US clinicians identified to operate beta sites for Oventus Medical will be accredited to deliver the O₂Vent™ T device in the US market in October 2016.

"Oventus is delivering on the goals we have set ourselves and we have an exciting future ahead of us," Chief Executive Neil Anderson said.

The company's devices contain an innovative airway which directs air around nasal, soft palate and tongue obstructions and delivers relief for sufferers of sleep apnoea and snoring.

Oventus has robust intellectual property protection in place around its innovations and continues to strengthen those positions.

The company has also established 3D printing manufacturing processes that enable it to rapidly meet demand as commercialisation of the devices continues. Clinical trials are also underway to provide further validation of its technology.

-ENDS-

For more information please contact:

Dr Mel Bridges, Chairman: M: 0413 051 600 (+61413051600)

Gavin Lower, WE Buchan: P: 03 8866 1215 or M: 0414 796 726

About Oventus Medical Limited

Oventus is a Brisbane based medical device company that is commercialising a suite of oral appliances for the treatment of sleep apnoea and snoring. Unlike other oral appliances, the Oventus devices have a unique and patented airway within the device that delivers air to the back of the mouth bypassing multiple obstructions from the nose, soft palate and tongue. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, the device actually prevents oral breathing. The O₂Vent™ range is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.¹

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, OSA, however many patients have difficulty tolerating CPAP². Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.³

¹ *Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.*

² *Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003*

³ *Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.*